Immune tolerance is one of those “small concept, huge payoff” topics: it connects autoimmunity, transplant rejection, hypersensitivity, and even tumor immune evasion. For Step 1, the test writers love asking where tolerance fails, what cell types normally enforce it, and which therapies exploit it—especially in transplant and autoimmune disease.
What “Immune Tolerance” Actually Means (Step-Precise Definition)
Immune tolerance is the immune system’s ability to remain unresponsive to specific antigens—classically self-antigens, but also sometimes allograft antigens (transplant) or fetal antigens (pregnancy).
Two big buckets:
- Central tolerance: happens during lymphocyte development in primary lymphoid organs
- T cells: thymus
- B cells: bone marrow
- Peripheral tolerance: happens after lymphocytes exit to the periphery (lymph nodes, spleen, tissues)
High-yield framing: Autoimmunity usually reflects failure of tolerance, and transplant immunology is essentially “your immune system refusing to tolerate non-self MHC.”
Why It Matters Clinically (Autoimmune + Transplant Angle)
In autoimmunity
Tolerance breaks → autoreactive lymphocytes activate → tissue injury via:
- Autoantibodies (type II/III hypersensitivity patterns)
- Autoreactive T cells (type IV patterns)
- Chronic inflammation → fibrosis and organ dysfunction
In transplant
Recipient immune system recognizes donor antigens (especially donor MHC) →:
- T-cell–mediated rejection (direct cytotoxicity + cytokines)
- Antibody-mediated rejection (complement, vascular injury)
Pathophysiology: Central Tolerance (The “Boot Camp” Checkpoints)
T-cell central tolerance (Thymus)
In the thymus, T cells undergo:
- Positive selection (cortex): must recognize self MHC
- Negative selection (medulla): must not bind self antigen strongly
Key high-yield molecule:
- AIRE (AutoImmune REgulator) expressed in thymic medullary epithelial cells
- Promotes expression of peripheral tissue antigens in thymus → deletes T cells that would attack them
Classic Step association:
- AIRE mutation → Autoimmune polyendocrine syndrome type 1 (APS-1)
- Autoimmune endocrine disease (e.g., hypoparathyroidism, adrenal insufficiency) + chronic mucocutaneous candidiasis
- Mechanism: failed negative selection
B-cell central tolerance (Bone marrow)
Autoreactive B cells can undergo:
- Receptor editing (change light chain to reduce self-reactivity)
- Clonal deletion
- Anergy
Step tip: “Receptor editing” is a favorite one-liner for B-cell tolerance.
First Aid cross-reference: Immunology—Tolerance, AIRE, and autoimmune syndromes (varies by edition; typically near hypersensitivity/autoimmunity tables).
Pathophysiology: Peripheral Tolerance (Where Most Exam Questions Live)
Even with central tolerance, some self-reactive cells escape. Peripheral tolerance keeps them quiet via:
1) Anergy (functional unresponsiveness)
- Occurs when a T cell recognizes antigen without appropriate costimulation
- The costimulation pearl:
- B7 (CD80/86) on APC binds CD28 on T cell → “green light”
- Without it → T cell becomes anergic
Clinical tie-in: Many immunosuppressants and checkpoint pathways manipulate this activation step.
2) Suppression by Tregs (Regulatory T cells)
Tregs are the “brakes”:
- CD4+, CD25+, FOXP3+
- Secrete IL-10 and TGF-β
- Suppress autoreactive T cells and dampen immune responses
Classic Step association:
- FOXP3 mutation → IPEX
- Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked
- Severe early-onset autoimmunity (e.g., eczema, diarrhea, type 1 diabetes)
3) Deletion (activation-induced cell death)
- Repeated stimulation → apoptosis (often via Fas-FasL pathway)
Classic Step association:
- Fas (CD95) mutation → Autoimmune lymphoproliferative syndrome (ALPS)
- Failure of lymphocyte apoptosis → lymphadenopathy + autoimmunity
4) Immune privilege (site-specific tolerance-ish behavior)
Certain sites reduce immune responses:
- Eye, testes, pregnant uterus/fetus, CNS (relative) Mechanisms include physical barriers, low MHC expression, local immunosuppressive cytokines.
Transplant Immunology Through the Lens of Tolerance (Very Testable)
How the recipient recognizes the graft
- Direct allorecognition: recipient T cells recognize donor APC presenting donor MHC
→ strong T-cell activation (especially early) - Indirect allorecognition: recipient APC presents donor peptides on recipient MHC
→ contributes to chronic processes
Rejection types (know the patterns)
| Type | Timing | Mechanism | Key Findings |
|---|---|---|---|
| Hyperacute | Minutes–hours | Preformed anti-donor antibodies (often anti-ABO or anti-HLA) → complement | Thrombosis, ischemia, necrosis |
| Acute | Days–weeks (or months if ↓ immunosuppression) | T cells ± antibodies | Endothelitis, interstitial lymphocytes |
| Chronic | Months–years | Chronic inflammation (T cells + antibodies) → smooth muscle proliferation | Fibrosis, vascular narrowing, “graft arteriosclerosis” |
High-yield tie-in: “Tolerance” in transplant is basically trying to prevent the acute/chronic processes without global immunodeficiency.
Clinical Presentation: How “Tolerance Failure” Shows Up
Autoimmune disease presentations (pattern recognition)
- Systemic symptoms: fatigue, fevers, weight loss
- Organ-specific:
- Endocrine: hypo/hyperthyroid symptoms, adrenal crisis, hypocalcemia
- GI: chronic diarrhea (IPEX)
- Skin: eczema-like rash (IPEX), photosensitivity (SLE)
- Joints: inflammatory arthritis
- Kidney: hematuria/proteinuria (immune complex disease)
Transplant rejection presentations
- Often nonspecific: fever, malaise, graft tenderness
- Organ dysfunction labs:
- Kidney: ↑ creatinine, ↓ urine output
- Liver: ↑ AST/ALT, ↑ bilirubin
- Heart: arrhythmias, ↓ EF
- Lung: dyspnea, ↓ oxygenation
Diagnosis: What You Actually Order (and What They’ll Test)
Autoimmunity (general approach)
- Inflammation markers: ESR/CRP (nonspecific)
- Autoantibodies (disease-specific patterns)
- Biopsy when organ involvement is critical (kidney, skin, etc.)
- Complement levels: decreased in some immune complex diseases (e.g., SLE)
Transplant rejection
- Biopsy is the gold standard (many vignettes emphasize this)
- Supporting tests:
- Rising creatinine (kidney), LFT abnormalities (liver), imaging to exclude obstruction/vascular complications
- Donor-specific antibodies (antibody-mediated rejection workup)
Treatment: How We Induce “Tolerance” Clinically (Without Calling It That)
Core immunosuppression strategies in transplant
Think in layers: block activation, block proliferation, deplete cells, reduce cytokine signals.
Block T-cell activation/costimulation
- Calcineurin inhibitors: cyclosporine, tacrolimus
- ↓ IL-2 transcription → ↓ T-cell activation
- CTLA-4–Ig (belatacept/abatacept concept): blocks B7-CD28
- Mechanism mirrors natural inhibitory signaling (CTLA-4 competes with CD28)
Block cytokine signaling / proliferation
- Sirolimus (rapamycin): inhibits mTOR → blocks IL-2 signaling → ↓ T-cell proliferation
- Azathioprine, mycophenolate, methotrexate (varies by context): antiproliferative
Deplete/neutralize immune mediators
- Antithymocyte globulin (T-cell depletion)
- Rituximab (anti-CD20) for B-cell mediated processes in some settings
- IVIG / plasmapheresis in antibody-mediated rejection (board-style associations)
First Aid cross-reference: Pharmacology—immunosuppressants (calcineurin inhibitors, sirolimus, mycophenolate, azathioprine, steroids) and transplant rejection patterns.
High-Yield Associations & “Classic Step Traps”
Must-know genes and syndromes
| Defect | What fails | Disease | Clue |
|---|---|---|---|
| AIRE mutation | Negative selection in thymus | APS-1 | Multiple endocrine autoimmunity + candidiasis |
| FOXP3 mutation | Treg development/function | IPEX | Early severe autoimmunity, enteropathy, eczema |
| Fas mutation | Peripheral deletion (apoptosis) | ALPS | Lymphadenopathy + autoimmune cytopenias |
Costimulation checkpoint (frequent concept)
- Signal 1: TCR recognizes antigen on MHC
- Signal 2: B7–CD28 costimulation
- No signal 2 → anergy (tolerance)
Transplant “hyperacute” = preformed antibodies
- Prior sensitization:
- Previous transplant
- Pregnancy
- Blood transfusions
- Path: complement activation → thrombosis → graft failure
How USMLE Likes to Ask Immune Tolerance
Common vignette templates:
- Kid with eczema + chronic diarrhea + type 1 diabetes → think IPEX (FOXP3, Tregs)
- Hypocalcemia + adrenal insufficiency + chronic mucocutaneous candidiasis → APS-1 (AIRE)
- Lymphadenopathy + autoimmune hemolytic anemia → ALPS (Fas)
- Transplant patient with sudden anuria minutes after surgery → hyperacute rejection
- Organ dysfunction days/weeks after transplant + biopsy shows lymphocytes → acute cellular rejection
Quick “If You Remember Nothing Else” Summary
- Central tolerance deletes strongly self-reactive cells (T cells: thymus; B cells: marrow).
- AIRE is required for thymic expression of peripheral antigens → prevents multi-organ autoimmunity.
- Peripheral tolerance is mainly anergy, Treg suppression (FOXP3; IL-10, TGF-β), and apoptotic deletion (Fas).
- Transplant rejection is the immune system failing to “tolerate” donor MHC; biopsy often confirms.
- Many immunosuppressants work by blocking T-cell activation (calcineurin) or costimulation (B7-CD28) or proliferation (mTOR).